Omega-3 for Fatty Liver: Evidence and UK Guidance

Omega-3 fatty acids for fatty liver disease have attracted growing interest as a potential dietary and supplementary intervention for one of the UK's most common liver conditions. Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, affects around one in three adults in the UK and is closely linked to obesity, type 2 diabetes, and raised blood lipids. EPA and DHA, the two most clinically relevant omega-3s, may help reduce liver fat and inflammation through several biological mechanisms. This article explains how omega-3s work, what the clinical evidence shows, appropriate doses and forms, potential risks, and how supplementation fits within a broader lifestyle approach.

What is fatty liver disease and who does it affect in the UK?

Fatty liver disease affects around one in three UK adults and is divided into MASLD (metabolic) and alcohol-related forms; early stages are often symptom-free and identified incidentally.

Fatty liver disease is a condition in which excess fat accumulates within liver cells, impairing normal liver function over time. It is broadly divided into two main types: metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD) and alcohol-related liver disease (ALD). The terminology is evolving: NICE guideline NG49 retains the title 'Non-alcoholic fatty liver disease (NAFLD)', while NHS England and many specialist societies have begun adopting MASLD and the related term MASH (metabolic dysfunction-associated steatohepatitis) to reflect a better understanding of the condition's metabolic origins.^[1] Both sets of terms remain in clinical use, and patients may encounter either.

MASLD/NAFLD is estimated to affect around one in three adults in the UK, according to NHS and British Liver Trust estimates, making it one of the most common liver conditions in the country.^[2] It is closely linked to obesity, type 2 diabetes, high blood pressure, and raised blood lipids, collectively known as metabolic syndrome. Many people have no symptoms in the early stages, and the condition is often identified incidentally during routine blood tests or abdominal imaging.

Without intervention, a proportion of people with MASLD can progress to MASH, where inflammation and liver cell damage occur alongside fat accumulation. A smaller number go on to develop fibrosis, cirrhosis, or liver failure. Early identification and lifestyle modification remain the cornerstone of management, as set out in NICE guideline NG49.

Alcohol-related fatty liver disease follows a similar pathological pattern but is driven by excessive alcohol consumption rather than metabolic factors. Both forms share the risk of progression if the underlying cause is not addressed.

When to seek help: Contact your GP promptly if you develop any of the following, as they may indicate significant liver disease requiring urgent assessment: yellowing of the skin or whites of the eyes (jaundice), dark urine or pale stools, swelling of the abdomen, vomiting blood or passing black tarry stools, or episodes of confusion or unusual drowsiness. Your GP can assess your risk of liver fibrosis using validated scoring tools such as the FIB-4 index or the NAFLD Fibrosis Score, and may arrange further tests or referral to a hepatology specialist if indicated.

How do omega-3 fatty acids work on a fatty liver?

EPA and DHA reduce liver fat by activating fat-burning pathways, suppressing fat production via SREBP-1c, and generating anti-inflammatory mediators called specialised pro-resolving mediators.

Omega-3 fatty acids reduce fat accumulation in the liver primarily by suppressing the production of triglycerides and promoting their breakdown through several complementary mechanisms. The two most clinically relevant omega-3s are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both found in oily fish and fish oil supplements. A third, alpha-linolenic acid (ALA), is found in plant sources such as flaxseed and walnuts, but is converted to EPA and DHA only inefficiently in the human body.

At a cellular level, EPA and DHA are thought to activate peroxisome proliferator-activated receptors (PPARs), a family of nuclear receptors that regulate genes involved in fatty acid oxidation.^[3] By upregulating fat-burning pathways and downregulating lipogenic (fat-producing) pathways, omega-3s may help shift the liver's metabolic balance away from fat storage. They also appear to suppress sterol regulatory element-binding protein-1c (SREBP-1c), a key transcription factor that drives the liver to manufacture new fat from carbohydrates.^[4]

Omega-3s additionally have anti-inflammatory properties that may be relevant in MASH, where hepatic inflammation drives disease progression. EPA and DHA are precursors to specialised pro-resolving mediators (SPMs), including resolvins and protectins, which actively resolve inflammatory responses rather than simply suppressing them.^[5][6] This dual action on both lipid metabolism and inflammation makes omega-3s a biologically plausible intervention for fatty liver disease.

It is important to note that these mechanisms have been characterised largely in laboratory and animal studies. The extent to which they translate into clinically meaningful liver improvements in humans is the subject of ongoing research, and the evidence base continues to evolve.

What does the evidence say about omega-3s and fatty liver disease?

Evidence supports omega-3s reducing liver fat and enzyme levels in MASLD, but NICE does not recommend them as a specific treatment due to limited long-term histological outcome data.

Clinical evidence suggests that omega-3 supplementation can reduce liver fat content in people with MASLD, though the magnitude of benefit and its translation into hard clinical outcomes remains under investigation. Multiple randomised controlled trials and systematic reviews have demonstrated reductions in liver triglyceride levels and improvements in liver enzyme markers such as alanine aminotransferase (ALT) with EPA and DHA supplementation compared with placebo.

A 2016 Cochrane systematic review (Musso et al., Cochrane Database of Systematic Reviews) examining omega-3 supplementation in NAFLD found evidence of benefit for liver fat and liver enzymes, but noted that the quality of evidence was low to moderate and that trials were generally short in duration and small in size. More recent meta-analyses, including those published between 2019 and 2024, have broadly supported these findings, with some reporting statistically significant reductions in hepatic steatosis as measured by ultrasound or magnetic resonance spectroscopy.

However, evidence for omega-3s improving liver fibrosis or reducing progression to cirrhosis is less robust. NICE guideline NG49 does not recommend omega-3 supplementation as a specific treatment for NAFLD/MASLD, reflecting the absence of high-quality long-term trial data demonstrating benefit on histological outcomes. The guideline does acknowledge that omega-3s may be considered for managing hypertriglyceridaemia in people with NAFLD.

Prescription-strength omega-3 preparations available in the UK include Vazkepa (icosapent ethyl) and Omacor (omega-3-acid ethyl esters). These are distinct from over-the-counter fish oil supplements and are licensed for specific indications: Vazkepa is MHRA-authorised to reduce cardiovascular risk in adults with elevated triglycerides who are already on statin therapy, while Omacor is authorised for severe hypertriglyceridaemia and as an adjunct after myocardial infarction.^[7][8] Neither is established as a treatment for MASLD within NHS clinical pathways, and patients should discuss the evidence with their GP or specialist before starting any supplementation.

How much omega-3 should you take, and which form works best?

Most MASLD trials used 1 to 4 grams of combined EPA and DHA daily; marine-derived sources are better studied than plant ALA, and algae-based supplements suit vegans or those with fish allergies.

There is no universally agreed therapeutic dose of omega-3 for fatty liver disease, as clinical trials have used a wide range of doses and formulations. Most research in MASLD has used combined EPA and DHA doses ranging from around 1 gram to 4 grams per day, with higher doses generally associated with greater reductions in liver fat and triglycerides in trial settings. However, these doses were used in supervised research settings, and self-prescribing high-dose supplements without medical guidance is not recommended.

In terms of form, EPA and DHA from marine sources (oily fish or fish oil capsules) are better studied and more bioavailable than ALA from plant sources. Some evidence suggests that triglyceride-form fish oils may be absorbed more readily than ethyl ester forms, though the clinical significance of this difference in the context of liver disease has not been firmly established, and the evidence is debated. Algae-derived omega-3 supplements provide EPA and DHA without fish and are a suitable option for people following a vegetarian or vegan diet, or for those with a fish or shellfish allergy.

For general cardiovascular health, the NHS recommends eating at least two portions of fish per week, one of which should be oily fish such as salmon, mackerel, sardines, or trout.^[16] This dietary approach provides meaningful amounts of EPA and DHA without the need for supplementation in most people. For those who do not eat fish, a supplement providing around 250 to 500 mg of combined EPA and DHA daily is a commonly cited reference range for general health maintenance, though this is below the doses used in most MASLD trials.

Pregnancy and breastfeeding: Pregnant women and those trying to conceive should avoid cod liver oil supplements, as these contain high levels of vitamin A (retinol), which can be harmful to a developing baby. Standard fish oil supplements (which do not contain vitamin A) may be taken, but anyone who is pregnant or breastfeeding should seek advice from their midwife or GP before starting high-dose omega-3 supplementation.

Fish or shellfish allergy: People with a known allergy to fish or shellfish should avoid fish-derived oil supplements and consider algae-derived EPA and DHA instead.

Anyone considering higher-dose omega-3 supplementation for liver health should speak to their GP first, particularly if they are taking anticoagulant medicines or have a bleeding disorder, as high doses can affect platelet function.

Are there any side effects or risks you should know about?

Common side effects are gastrointestinal; doses above 3 g per day can prolong bleeding time and raise atrial fibrillation risk, so consult your GP if you take anticoagulants or have heart rhythm issues.

Omega-3 fatty acid supplements are generally well tolerated at doses used for general health, but higher doses carry a greater risk of side effects and interactions. The most commonly reported adverse effects are gastrointestinal and include:

• Fishy aftertaste or burping

• Nausea or stomach discomfort

• Loose stools or diarrhoea

• Reflux symptoms

Taking supplements with food, choosing enteric-coated capsules, or storing them in the freezer can help reduce these effects for many people.

At higher doses (typically above 3 grams per day of combined EPA and DHA), omega-3s can prolong bleeding time by reducing platelet aggregation.^[11] This is clinically relevant for people taking anticoagulants such as warfarin or direct oral anticoagulants (DOACs), antiplatelet medicines such as aspirin or clopidogrel, or those scheduled for surgery. People in these groups should inform their GP or pharmacist before starting supplementation.

High-dose omega-3 supplementation has also been associated with a modest increase in low-density lipoprotein (LDL) cholesterol in some individuals, particularly with ethyl ester formulations. This is worth monitoring in people who already have elevated LDL or established cardiovascular disease.

Atrial fibrillation: Evidence from large cardiovascular trials, including trials of high-dose icosapent ethyl, has raised a signal for an increased risk of atrial fibrillation (AF) at doses of around 4 grams per day.^[13][14] People with a personal or family history of AF should discuss this risk with their GP or cardiologist before taking high-dose omega-3 supplements.

Pregnancy: Pregnant women and those trying to conceive should avoid cod liver oil due to its high vitamin A content. Seek advice from a midwife or GP before taking high-dose omega-3 supplements during pregnancy or breastfeeding.

Fish or shellfish allergy: Avoid fish-derived oil supplements and consider algae-derived EPA and DHA as an alternative.

Fish oil supplements are not medicines regulated by the MHRA in the same way as licensed pharmaceutical products, so quality and purity can vary between brands. Contamination with heavy metals or environmental pollutants is a theoretical concern with lower-quality products; choosing supplements that carry independent quality certification can help mitigate this risk.

If you experience unexpected symptoms after starting omega-3 supplements, contact your GP. Suspected adverse reactions to any product, including supplements, can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Diet, lifestyle and omega-3s: getting the most from your treatment

Omega-3s are most effective alongside weight loss, a Mediterranean-style diet, and regular exercise, which NICE identifies as the primary evidence-based interventions for MASLD.

Omega-3 supplementation is most effective when used as part of a broader dietary and lifestyle approach, rather than as a standalone intervention for fatty liver disease. Supplements do not replace clinical assessment or the lifestyle changes that form the foundation of MASLD management.

NICE guideline NG49 is clear that weight loss through a combination of dietary change and increased physical activity is the most evidence-based intervention for MASLD. Clinical studies have shown that a reduction of 7 to 10 percent of body weight is associated with meaningful improvements in liver histology, including reductions in liver fat and inflammation.

A Mediterranean-style diet, which is naturally rich in oily fish, olive oil, vegetables, legumes, and wholegrains, is widely recommended for people with MASLD. This dietary pattern provides EPA and DHA from food sources alongside a range of anti-inflammatory nutrients and fibre, and has been associated with reduced liver fat and improved metabolic markers in observational and interventional studies. Reducing intake of ultra-processed foods, added sugars, and refined carbohydrates is particularly important, as fructose and excess carbohydrate intake directly drive hepatic lipogenesis.

Regular physical activity, including both aerobic exercise and resistance training, independently reduces liver fat content and improves insulin sensitivity, which is a key driver of MASLD. NHS guidance recommends at least 150 minutes of moderate-intensity activity per week for adults, and even modest increases in activity have been shown to benefit liver health.^[15]

Alcohol should be minimised or avoided entirely in people with any form of fatty liver disease, as even moderate consumption can accelerate liver damage. People with MASLD who also drink alcohol above recommended limits face a compounded risk of progression.

If your GP has identified a risk of liver fibrosis using a scoring tool such as FIB-4, they may arrange further assessment or refer you to a hepatology specialist. It is important to attend these appointments and to discuss any supplements you are taking, as some may interact with prescribed medicines or affect liver enzyme results.

For those seeking structured support with weight management and metabolic health, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate treatment options may be considered alongside lifestyle guidance.

Scientific References

1. Non-alcoholic fatty liver disease (NAFLD): assessment and management [NG49].
2. Non-alcoholic fatty liver disease (NAFLD).
3. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Schoonjans K et al..
4. N-3 polyunsaturated fatty acids suppress insulin-induced SREBP-1c. Howell G 3rd et al..
5. Integrating downstream mediators of Omega-3 fatty acids into enteral nutrition — expert panel consensus.
6. Effects of Omega-3 Supplementation on Inflammation and Recovery in Sports: A Meta-Analysis.
7. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events [TA805].
8. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). Bhatt DL et al..
9. Omega 3-acid-ethyl esters 1000mg soft capsules (SmPC).
10. Omega-3 acid ethyl esters-containing medicinal products — referral (secondary prevention after myocardial infarction).
11. Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin.
12. Ethyl EPA and ethyl DHA cause similar and differential changes in plasma lipid concentrations and lipid metabolism.
13. Cardiovascular Benefits of Icosapent Ethyl in Patients With… (REDUCE-IT AF analysis). Olshansky B et al..
14. Omega-3 Fatty Acids and Arrhythmias.
15. Physical activity guidelines for adults aged 19 to 64.
16. Fish and shellfish nutrition.
17. The Impact of Omega-3 Fatty Acids on Triglyceride Levels in Patients with MASLD: A Meta-Analysis of RCTs.

Frequently Asked Questions